The Global Mono Hepatitis B Vaccine Market was valued at USD 1.06 Billion in 2023 and is projected to reach USD 1.22 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 1.5% during the forecast period (2023-2032). This growth is propelled by expanding immunization programs worldwide, increased awareness of Hepatitis B prevention, and growing government mandates for newborn and healthcare worker vaccinations.
As public health initiatives intensify to eliminate viral hepatitis, pharmaceutical innovators are developing advanced vaccine formulations with improved efficacy and stability. This analysis profiles the Top 10 Companies in the Mono Hepatitis B Vaccine Market—global pharmaceutical leaders and specialized vaccine manufacturers delivering critical immunization solutions across 160+ countries.
🔟 1. GlaxoSmithKline (GSK)
Headquarters: Brentford, United Kingdom
Key Offering: Engerix-B®
GSK dominates the Hepatitis B vaccine landscape with Engerix-B, one of the most widely administered vaccines globally. The company maintains strategic partnerships with WHO, UNICEF, and governments to supply vaccines to developing nations through tiered pricing models.
Recent Developments:
- Supplied 87 million Hepatitis B vaccine doses in 2023
- Received WHO prequalification for new multi-dose vial presentation
- Investing €300 million in Belgian vaccine production facilities
Download FREE Sample Report: Mono Hepatitis B Vaccine Market – View in Detailed Research Report
9️⃣ 2. China National Pharmaceutical Group (Sinopharm)
Headquarters: Beijing, China
Key Offering: HepB (Yeast-Derived)
Sinopharm is China’s vaccine powerhouse, producing both plasma-derived and recombinant Hepatitis B vaccines. The company supplies over 80% of China’s domestic Hepatitis B vaccine demand and exports to emerging markets across Asia and Africa.
Recent Developments:
- Annual production capacity of 250 million Hepatitis B vaccine doses
- Developing thermostable vaccine formulations for tropical climates
8️⃣ 3. Merck & Co., Inc.
Headquarters: Kenilworth, New Jersey, USA
Key Offering: Recombivax HB®
Merck pioneered recombinant Hepatitis B vaccine technology with Recombivax HB, first approved in 1986. The company maintains strong market share in North America and Europe through hospital networks and retail pharmacy channels.
Recent Developments:
- Developing hexavalent pediatric combination vaccines including HepB
- Expanding cold chain distribution infrastructure in emerging markets
7️⃣ 4. Shenzhen Kangtai Biological Products Co., Ltd.
Headquarters: Shenzhen, China
Key Offering: HepB (Hansenula Polymorpha)
Kangtai specializes in innovative yeast-derived Hepatitis B vaccines with improved stability profiles. As China’s largest vaccine producer by volume, the company supplies 40% of the national immunization program requirements.
Recent Developments:
- Launched new 60-dose presentation for